EA202090715A1 - Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени - Google Patents

Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени

Info

Publication number
EA202090715A1
EA202090715A1 EA202090715A EA202090715A EA202090715A1 EA 202090715 A1 EA202090715 A1 EA 202090715A1 EA 202090715 A EA202090715 A EA 202090715A EA 202090715 A EA202090715 A EA 202090715A EA 202090715 A1 EA202090715 A1 EA 202090715A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alcoholic
liver
steathepatitis
dystrophies
invasive diagnostics
Prior art date
Application number
EA202090715A
Other languages
English (en)
Inventor
Реми Анф
Женевьев Кордоннье
Джон Брозек
Original Assignee
Женфит
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Женфит filed Critical Женфит
Publication of EA202090715A1 publication Critical patent/EA202090715A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новому неинвазивному способу диагностики неалкогольной жировой дистрофии печени, в частности, неалкогольного стеатогепатита и/или фиброза печени.
EA202090715A 2017-09-18 2018-09-14 Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени EA202090715A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306201 2017-09-18
PCT/EP2018/074975 WO2019053233A1 (en) 2017-09-18 2018-09-14 NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS

Publications (1)

Publication Number Publication Date
EA202090715A1 true EA202090715A1 (ru) 2020-07-15

Family

ID=60001810

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090715A EA202090715A1 (ru) 2017-09-18 2018-09-14 Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени

Country Status (14)

Country Link
US (1) US11519034B2 (ru)
EP (1) EP3684954A1 (ru)
JP (1) JP7424981B2 (ru)
KR (1) KR20200051676A (ru)
CN (1) CN111065748B (ru)
BR (1) BR112020004439A2 (ru)
CA (1) CA3071219A1 (ru)
EA (1) EA202090715A1 (ru)
IL (1) IL272465A (ru)
MX (1) MX2020002532A (ru)
PH (1) PH12020500354A1 (ru)
SG (1) SG11202001111QA (ru)
WO (1) WO2019053233A1 (ru)
ZA (1) ZA202001528B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900005700A1 (it) * 2019-04-12 2020-10-12 Metadeq Ltd Nuovo marcatore di patologia e suoi usi
CN114630660A (zh) * 2019-10-28 2022-06-14 基恩菲特公司 具有抗氧化特性的联合疗法
CN111549123B (zh) * 2020-06-12 2022-10-21 中山大学附属第三医院 环状rna 0089762的检测试剂盒及其应用
AU2021322057A1 (en) * 2020-08-03 2023-03-30 Genfit Method for nash risk assessment
US11820754B2 (en) 2020-08-25 2023-11-21 Eli Lilly And Company Polymorphs of an SSAO inhibitor
WO2022104289A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Use of pharmaceutical doses of niacin, or an analog thereof, for the regression or reversal of fibrosis and/or liver cirrhosis
CN112712896B (zh) * 2021-03-26 2023-03-07 深圳市绘云生物科技有限公司 用于受试体检测非酒精性脂肪性肝病状态的诊断装置及计算机系统
WO2024010753A1 (en) * 2022-07-06 2024-01-11 Georgetown University Mirna biomarkers and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
ES2527438T3 (es) * 2006-08-08 2015-01-26 Metabolon, Inc. Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos
FR2953220B1 (fr) 2009-12-01 2012-11-23 Oreal Signature microarn de la differenciation epidermique et utilisations
US9221751B2 (en) * 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2013166363A2 (en) * 2012-05-03 2013-11-07 The Johns Hopkins University Methods and compositions useful for diagnosing inflammatory bowel disease-associated neoplasia
JP2018518169A (ja) 2015-06-05 2018-07-12 レグルス セラピューティクス インコーポレイテッド 非アルコール性脂肪肝疾患バイオマーカー
HUE056299T2 (hu) * 2015-09-14 2022-02-28 Genfit Eljárások nem-alkoholos steatohepatitis diagnosztizálására és kiértékelésére

Also Published As

Publication number Publication date
KR20200051676A (ko) 2020-05-13
WO2019053233A1 (en) 2019-03-21
JP7424981B2 (ja) 2024-01-30
AU2018332318A1 (en) 2020-02-20
PH12020500354A1 (en) 2021-01-25
CN111065748B (zh) 2024-04-09
US11519034B2 (en) 2022-12-06
MX2020002532A (es) 2020-07-20
CA3071219A1 (en) 2019-03-21
JP2021502109A (ja) 2021-01-28
BR112020004439A2 (pt) 2020-10-06
CN111065748A (zh) 2020-04-24
SG11202001111QA (en) 2020-03-30
ZA202001528B (en) 2024-09-25
IL272465A (en) 2020-03-31
EP3684954A1 (en) 2020-07-29
US20200216901A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
EA202090715A1 (ru) Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
EA201892201A1 (ru) Неинвазивная диагностика неалкогольного стеатогепатита
WO2016098079A3 (en) Compositions and methods for antibodies targeting bmp6
EP3173464A4 (en) Powdered fat/oil composition, food including powdered fat/oil composition, and methods for producing same
EP3117838A4 (en) Composition containing sophorolipid, physiologically active substance and oil and fat, and method of producing said composition
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
EP3411011A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH
AR109819A1 (es) Composiciones edulcorantes que tienen una calidad de sabor mejorada que comprenden alulosa y sal, y un método para mejorar la calidad de sabor de alulosa utilizando sal
FI20145363A (fi) Menetelmä härkäpapujen konvertoimiseksi, ravitsemuksellisesti arvokkaat härkäpapuainesosat ja niiden käyttö
SG11202102684VA (en) Treatment for non-alcoholic fatty liver disease
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
MX2020003812A (es) Composicion de proteinas de guisante que tiene calidad nutricional mejorada.
WO2017029558A3 (en) Methods for improving health of farmed fish
PH12019501327A1 (en) Umami taste enhancing agent
EA201892722A2 (ru) Мелассовый порошок и способ его получения
WO2018037225A3 (en) Enzyme compositions and diagnostics for use in enterometabolic dysfunction
AU2016330230B2 (en) Low SAFA fat composition, aerated emulsion and method
WO2015185993A3 (en) Methods for improving fillet quality in farmed fish
ZA201902056B (en) Compositions and methods of pet food
BR112017013928A2 (pt) composição alimentar e método de uso.
EA202090569A1 (ru) Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.